Valeant Re-Appoints Board Member
This article was originally published in Scrip
Valeant Pharmaceuticals International Plc. has reappointed Mason Morfit to its board of directors – effective immediately. Morfit originally served on the board from 2007 to 2014 and is currently president of ValueAct Capital, a governance-orientated investment fund. He is also on the board for Microsoft Corp. and is a former director of CR Bard Inc., Immucor Inc., Advanced Medical Optics, Solexa Inc., and MSD Performance, Inc.